139 related articles for article (PubMed ID: 34349852)
1. Personalized Medicine in Ovarian Cancer: A Perspective From Mexico.
Fernandez-Garza LE; Dominguez-Vigil IG; Garza-Martinez J; Valdez-Aparicio EA; Barrera-Barrera SA; Barrera-Saldana HA
World J Oncol; 2021 Aug; 12(4):85-92. PubMed ID: 34349852
[TBL] [Abstract][Full Text] [Related]
2. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
[TBL] [Abstract][Full Text] [Related]
3. Current Status of Patient-Derived Ovarian Cancer Models.
Maru Y; Hippo Y
Cells; 2019 May; 8(5):. PubMed ID: 31130643
[TBL] [Abstract][Full Text] [Related]
4. Mortality among oral contraceptive users: 20 year follow up of women in a cohort study.
Vessey MP; Villard-Mackintosh L; McPherson K; Yeates D
BMJ; 1989 Dec; 299(6714):1487-91. PubMed ID: 2514858
[TBL] [Abstract][Full Text] [Related]
5. Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.
Mandilaras V; Vernon M; Meryet-Figuière M; Karakasis K; Lambert B; Poulain L; Oza A; Denoyelle C; Lheureux S
Expert Opin Biol Ther; 2017 Aug; 17(8):927-943. PubMed ID: 28641048
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer.
Lu T; Zhang L; Zhu W; Zhang Y; Zhang S; Wu B; Deng N
Front Oncol; 2020; 10():1529. PubMed ID: 32984003
[TBL] [Abstract][Full Text] [Related]
7. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
8. New insight into NANOG: A novel therapeutic target for ovarian cancer (OC).
Mahalaxmi I; Devi SM; Kaavya J; Arul N; Balachandar V; Santhy KS
Eur J Pharmacol; 2019 Jun; 852():51-57. PubMed ID: 30831081
[TBL] [Abstract][Full Text] [Related]
9. Construction of a novel prognostic-predicting model correlated to ovarian cancer.
Tang W; Li J; Chang X; Jia L; Tang Q; Wang Y; Zheng Y; Sun L; Feng Z
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32716025
[TBL] [Abstract][Full Text] [Related]
10. KLHL14, an ovarian and endometrial-specific gene, is over-expressed in ovarian and endometrial cancer.
Han M; Yang HJ; Lin Q
Math Biosci Eng; 2019 Dec; 17(2):1702-1717. PubMed ID: 32233603
[TBL] [Abstract][Full Text] [Related]
11. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
12. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
El Bairi K; Kandhro AH; Gouri A; Mahfoud W; Louanjli N; Saadani B; Afqir S; Amrani M
Cell Oncol (Dordr); 2017 Apr; 40(2):105-118. PubMed ID: 27981507
[TBL] [Abstract][Full Text] [Related]
13. Worldwide variations in the lifetime probability of reproductive cancer in women: implications of best-case, worst-case, and likely-case assumptions about the effect of oral contraceptive use.
Petitti DB; Porterfield D
Contraception; 1992 Feb; 45(2):93-104. PubMed ID: 1559340
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients-A Nationwide Cohort Study.
Santala EEE; Artama M; Pukkala E; Visvanathan K; Staff S; Murtola TJ
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925829
[TBL] [Abstract][Full Text] [Related]
15. Non-cancer death causes after ovarian cancer diagnosis: A population-based cohort.
Elmehrath AO; Afifi AM; Abdel-Malek R
J Obstet Gynaecol Res; 2021 May; 47(5):1884-1891. PubMed ID: 33751749
[TBL] [Abstract][Full Text] [Related]
16. Treatment of ovarian cancer beyond chemotherapy: are we hitting the target?
Garces ÁH; Dias MS; Paulino E; Ferreira CG; de Melo AC
Cancer Chemother Pharmacol; 2015 Feb; 75(2):221-34. PubMed ID: 25212538
[TBL] [Abstract][Full Text] [Related]
17. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.
Hirasawa A; Imoto I; Naruto T; Akahane T; Yamagami W; Nomura H; Masuda K; Susumu N; Tsuda H; Aoki D
Oncotarget; 2017 Dec; 8(68):112258-112267. PubMed ID: 29348823
[TBL] [Abstract][Full Text] [Related]
19. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
[TBL] [Abstract][Full Text] [Related]
20. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S
J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
